C12N5/0697

PACKAGING OF CULTURED TISSUE
20230059527 · 2023-02-23 ·

The invention is in the field of cultured meat. In particular the invention is related to a method for aseptic packaging of cultured tissue and a system suitable for this method. The method comprises the steps of producing the cultured tissue, harvesting the cultured tissue, transferring the cultured tissue to a sterile package and sealing the sterile package, wherein all steps are executed under aseptic conditions.

MULTIPLE COMPONENT GRAFTS FOR TREATING TISSUE DEFECTS AND METHODS FOR MAKING AND USING SAME
20230057906 · 2023-02-23 ·

Multiple component grafts are provided for treatment of tissue defects and comprise two or more components, each of which is a tissue-derived matrix and at least two of which are derived from different types of tissue. For example, a first component may be a matrix derived from cartilage tissue such as cartilage fibers with or without viable cells, cartilage particles with or without viable cells, or combinations of any two or more such cartilage-derived matrices. A second component may be a matrix derived from bone tissue such as mineralized or demineralized cortical bone fibers, viable cancellous bone matrix (e.g., cryopreserved or lyophilized chips, particulates, powder, sheets, putty, flowable fluid, etc.), demineralized or demineralized cancellous bone matrix (chips, particulates, powder, sheets, putty, flowable fluid, etc.), or combinations of any two or more of such bone-derived matrices. Also provided are methods for making and using such multiple component grafts.

BLOOD-BRAIN-BARRIER SYSTEMS
20230056360 · 2023-02-23 ·

Disclosed herein is a device comprising a microelectrode comprising cells cultured on a surface of the microelectrode and a porous membrane comprising an upper surface comprising cultured cells. Further, devices and methods for in in-vitro models of the blood-brain barrier (BBB) and for modeling the transport across this barrier are disclosed.

BIOREACTOR SYSTEMS

Bioreactor systems can include a first frame and a second frame, a well plate, a motor plate, a motor, and a controller. The first frame may define a well plate inset and standoff insets for a first set of metal standoffs. The second frame may define a plurality of mounts and a plurality of insets for a second set of metal standoffs. A gear may be positioned in each of the plurality of mounts. A paddle may be coupled to each of the gears. The well plate can be positioned within the well plate inset. The motor plate can be supported by and connected to the first set of metal standoffs and the second set of metal standoffs. The motor can be mounted on the motor plate and operatively connected to one of the plurality of gears.

METHOD AND KIT FOR VESSEL FORMATION USING SMS STEM CELL-PRODUCED ECM AND SUBSTRATES
20220364039 · 2022-11-17 ·

Disclosed herein are methods of inducing endothelial cell reorganization or differentiation to form micro- and macrovessel structures using an extracellular matrix, such as one derived from small mobile stem (SMS) cells, and a substrate, which can also be coated in molecules or otherwise physically manipulated to cause localized effects on reorganization Also disclosed is a kit implementation for performing endothelial cell reorganization.

Method of making in vivo human small intestine organoids from pluripotent stem cells

Disclosed are methods for making a vascularized hollow organ derived from human intestinal organoid (HIOs). The HIOs may be obtained from human embryonic stem cells (ESC's) and/or induced pluripotent stem cells (iPSCs), such that the HIO forms mature intestinal tissue. Also disclosed are methods for making a human intestinal tissue containing a functional enteric nervous system (ENS).

METHODS OF FUNCTIONAL VASCULARIZATION OF PANCREATIC ISLETS AND BETA-CELL ORGANOIDS
20220354901 · 2022-11-10 · ·

The instant disclosure is directed to a method for vascularizing a pancreatic islet comprising culturing the pancreatic islet or β-cells with an endothelial cell comprising an exogenous nucleic acid encoding an ETV2 transcription factor under conditions wherein the endothelial cell expresses the ETV2 transcription factor. The instant disclosure is further directed to a method for making a vascularized β-cell organoid comprising culturing the pancreatic islet or β-cells with an endothelial cell comprising an exogenous nucleic acid encoding an ETV2 transcription factor under conditions wherein the endothelial cell expresses the ETV2 transcription factor. Disclosed also are vascularized islets and vascularized β-cell organoids produced by the methods of the instant disclosure, as well as methods for using the same.

MICROPHYSIOLOGICAL 3-D PRINTING AND ITS APPLICATIONS

The systems and methods of the present disclosure can be used to generate systems and models that are physiologically relevant to the human and animal system. These physiological conditions can be designed to mimic the actual human condition for cell differentiation and proliferation. The system and methods of this present disclosure allow the formation of an appropriate biomaterial to mimic that which exists in a human or animal scaffold. Utilizing 3D printing technology, a hydrogel scaffold can be printed at various resolution very close to human physiological geometry. Additionally, the architecture can be optimized for the selected application and appropriate cells can be seeded on the scaffold prior to testing.

SUSPENSION-BASED 3D CULTURE METHOD FOR ORGANOIDS

Hybrid suspension cultures supplementing soluble extracellular matrix (ECM) for growth of organoids is disclosed. Viable lung organoid from epithelial, endothelial, and fibroblast human stable cell lines in suspension culture are also disclosed.

ENGINEERED TISSUE CONSTRUCTS

A modular engineered tissue construct includes a plurality of fused self-assembled, scaffold-free, high-density cell aggregates. At least one cell aggregate includes a plurality of cells and a plurality of biocompatible and biodegradable nanoparticles and/or microparticles that are incorporated within the cell aggregates. The nanoparticles and/or microparticles acting as a bulking agent within the cell aggregate to increase the cell aggregate size and/or thickness and improve the mechanical properties of the cell aggregate as well as to deliver bioactive agents.